Overview

Founded in 1995, Jiangsu Hansoh Pharmaceutical Group Co., Ltd. is an innovation-driven pharmaceutical company integrating the R&D, manufacturing, and sales of drugs. As a principal subsidiary of Hansoh Pharma (03692.HK), the Company is committed to improving human health through continuous innovation, focusing mainly on the fields of oncology, anti-infections, CNS diseases, metabolic diseases, as well as autoimmune diseases. The Company has maintained its position for a number of consecutive years in the Top 100 Pharmaceutical Companies in the global market and in the top 3 among China’s Best Industrial Enterprises in the Pharmaceutical R&D Pipeline, and is a key national high-tech enterprise and national technological innovation demonstration enterprise.

Expand outstanding R&D capabilities with over 20 years of R&D experience, the Company has established a number of state-level R&D centers, such as National Enterprise Technology Centers, Postdoctoral Research Stations, and State Key Laboratories. The Company has highly efficient capabilities in the discovery of innovative drugs, with R&D efforts covering the fields of peptides, biologics, small molecules, ADC drugs, siRNAs and different modalities related platforms. The Company has commenced 60 major national scientific and technological projects; has won two gold medals in China Patent Awards and two prestige prizes in the National Scientific and Technological Progress Awards. Hansoh has also been granted more than 600 invention patents in China and abroad; and has participated in establishing more than 200 national pharmaceutical standards.

Jiangsu Hansoh Pharma has so far marketed 7 innovative drugs, and has more than 60 clinical trials of innovative drug candidates being investigated, covering 40 innovative drug candidates, forming a competitive pipeline. Our innovative drugs on the market include: Saint Luolai (Pegmolesatide Injection）, the only marketed EPO Mimetic Peptide (EMP) worldwide; Ameile (aumolertinib mesylate tablets), China's first independently-developed third-generation EGFR-TKI; XINYUE (inebilizumab injections), the first global humanized CD19 monoclonal antibody for treating AQP4 antibody-positive NMOSD; Hengmu (tenofovir amibufenamide tablets), the first wholly developed oral dose medicine indicated for the treatment of hepatitis B virus (HBV) infection in China; Hansoh Xinfu (flumatinib mesylate tablets), China's independently-developed novel second-generation TKI for chronic myeloid leukemia; Fulaimei (PEG-loxenatide for injection), China's first independently-developed innovative GLP-1RA weekly formulation and the world's first PEGylated GLP-1RA weekly formulation; and Mailingda (morinidazole sodium chloride injection),the world's first innovative nitroimidazole anti-anaerobic drug in 40 years, seven innovative drugs have been included in the National Reimbursement Drug List. In 2024, the proportion of revenue from innovative drugs and cooperative products to total revenue increased to 77.3%, and Jiangsu Hansoh Pharma has successfully transformed itself into an innovative biopharma company.

Jiangsu Hansoh Pharma has always maintained dynamic consistency with global advanced access levels by continuously designing and building production facilities and production lines in accordance with international advanced standards and using advanced production equipment. Our production quality system has been officially certified by FDA in the United States, EMA of the European Union, and PMDA in Japan, and finished preparations and APIs have been approved for marketing in Europe, America, Japan, etc.

Looking ahead, Jiangsu Hansoh Pharma will further deepen its innovation-driven strategy, targeting the unmet clinical needs of Chinese and international patients, and develop more innovative drugs to improve the quality of human life.